First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

Isikdogan, A.Turk, H.Bilir, C.Sendur, M.Karabulut, B.Artac, M.Cicin, I.2024-04-242024-04-2420220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.04.180https://hdl.handle.net/11468/15132ESMO 24th World Congress on Gastrointestinal Cancer -- JUN 29-JUL 02, 2022 -- Barcelona, SPAIN[Abstract Not Available]eninfo:eu-repo/semantics/openAccess[No Keyword]First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysisFirst-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysisConference Object33S281S281WOS:00082382650010310.1016/j.annonc.2022.04.180Q1